Nothing Special   »   [go: up one dir, main page]

DK3028564T5 - Dyremodeller og terapeutiske molekyler - Google Patents

Dyremodeller og terapeutiske molekyler Download PDF

Info

Publication number
DK3028564T5
DK3028564T5 DK16151214.0T DK16151214T DK3028564T5 DK 3028564 T5 DK3028564 T5 DK 3028564T5 DK 16151214 T DK16151214 T DK 16151214T DK 3028564 T5 DK3028564 T5 DK 3028564T5
Authority
DK
Denmark
Prior art keywords
animal models
therapeutic molecules
therapeutic
molecules
models
Prior art date
Application number
DK16151214.0T
Other languages
English (en)
Other versions
DK3028564T3 (da
DK3028564T4 (da
Inventor
Allan Bradley
E-Chiang Lee
Qi Liang
Wei Wang
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43428834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3028564(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0911846.4A external-priority patent/GB0911846D0/en
Priority claimed from GB0913102A external-priority patent/GB0913102D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of DK3028564T3 publication Critical patent/DK3028564T3/da
Application granted granted Critical
Publication of DK3028564T4 publication Critical patent/DK3028564T4/da
Publication of DK3028564T5 publication Critical patent/DK3028564T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK16151214.0T 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler DK3028564T5 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22396009P 2009-07-08 2009-07-08
GBGB0911846.4A GB0911846D0 (en) 2009-07-08 2009-07-08 Animal models and therapeutic molecules
GB0913102A GB0913102D0 (en) 2009-07-28 2009-07-28 Animal models and therapeutic molesules
US35566610P 2010-06-17 2010-06-17
EP12194977.0A EP2604110B1 (en) 2009-07-08 2010-07-07 Animal models and therapeutic molecules

Publications (3)

Publication Number Publication Date
DK3028564T3 DK3028564T3 (da) 2017-11-13
DK3028564T4 DK3028564T4 (da) 2024-04-22
DK3028564T5 true DK3028564T5 (da) 2024-04-29

Family

ID=43428834

Family Applications (12)

Application Number Title Priority Date Filing Date
DK12171791.2T DK2517556T4 (da) 2009-07-08 2010-07-07 Fremgangsmåde til punkt-specifik rekombination, gnavere og gnaverceller i stand til at udtrykke kimære antistoffer eller kæder
DK19207050.6T DK3622813T4 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK14170196.1T DK2798950T4 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK17174426.1T DK3241435T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK16151215.7T DK3028565T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK12171793.8T DK2517557T4 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK12194977.0T DK2604110T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK16151214.0T DK3028564T5 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK14176740.0T DK2792236T4 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK12194970.5T DK2564695T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK10734546.4T DK2421357T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK19207053.0T DK3622815T3 (da) 2009-07-08 2010-07-07 Gnavermodeller og terapeutiske molekyler

Family Applications Before (7)

Application Number Title Priority Date Filing Date
DK12171791.2T DK2517556T4 (da) 2009-07-08 2010-07-07 Fremgangsmåde til punkt-specifik rekombination, gnavere og gnaverceller i stand til at udtrykke kimære antistoffer eller kæder
DK19207050.6T DK3622813T4 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK14170196.1T DK2798950T4 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK17174426.1T DK3241435T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK16151215.7T DK3028565T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK12171793.8T DK2517557T4 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK12194977.0T DK2604110T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK14176740.0T DK2792236T4 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK12194970.5T DK2564695T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK10734546.4T DK2421357T3 (da) 2009-07-08 2010-07-07 Dyremodeller og terapeutiske molekyler
DK19207053.0T DK3622815T3 (da) 2009-07-08 2010-07-07 Gnavermodeller og terapeutiske molekyler

Country Status (23)

Country Link
US (33) US20120204278A1 (da)
EP (19) EP4215043A1 (da)
JP (7) JP5944312B2 (da)
KR (1) KR101875233B1 (da)
CN (2) CN105340834B (da)
AU (4) AU2010269978B2 (da)
BR (1) BR112012000536A2 (da)
CA (1) CA2767436A1 (da)
CY (1) CY1126083T1 (da)
DK (12) DK2517556T4 (da)
ES (8) ES2403087T3 (da)
HK (5) HK1180535A1 (da)
HR (2) HRP20130253T1 (da)
HU (2) HUE055817T2 (da)
LT (1) LT3241435T (da)
NO (1) NO2792236T3 (da)
NZ (1) NZ597481A (da)
PL (4) PL3241435T3 (da)
PT (4) PT2421357E (da)
SG (2) SG177380A1 (da)
SI (2) SI3241435T1 (da)
SM (1) SMT201300046B (da)
WO (1) WO2011004192A1 (da)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
NZ592308A (en) 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP4215043A1 (en) 2009-07-08 2023-07-26 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
NZ601171A (en) 2010-03-31 2014-11-28 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
MX2012015298A (es) * 2010-06-22 2013-05-01 Regeneron Pharma Ratones con cadena ligera hibrida.
AU2011286185B2 (en) 2010-07-26 2014-08-14 Trianni, Inc. Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
SG10201912639SA (en) * 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
HRP20191895T4 (hr) * 2011-02-25 2023-05-12 Regeneron Pharmaceuticals, Inc. Adam6 miševi
JP6211931B2 (ja) 2011-03-09 2017-10-11 セル・シグナリング・テクノロジー・インコーポレイテツド モノクローナル抗体を作製するための方法および試薬
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
LT3572517T (lt) * 2011-08-05 2021-04-26 Regeneron Pharmaceuticals, Inc. Humanizuotos universalios lengvosios grandinės pelės
DK3311661T3 (da) 2011-09-19 2022-07-11 Kymab Ltd Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
GB2501753A (en) * 2012-05-04 2013-11-06 Kymab Ltd Human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
GB2495083A (en) * 2011-09-26 2013-04-03 Kymab Ltd Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates
EP2763699A4 (en) 2011-10-03 2015-05-20 Univ Duke VACCINE
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
RS61455B1 (sr) * 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
LT3272214T (lt) 2011-10-28 2020-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
NZ734532A (en) * 2011-10-28 2022-12-23 Regeneron Pharma Genetically modified major histocompatibility complex mice
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CN104159444B (zh) * 2011-12-20 2017-09-01 瑞泽恩制药公司 人源化的轻链小鼠
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
WO2013134263A1 (en) * 2012-03-06 2013-09-12 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9334334B2 (en) 2012-03-16 2016-05-10 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SI2825037T1 (sl) 2012-03-16 2019-08-30 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo PH občutljiva zaporedja imunoglobulina
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SG10201913429WA (en) * 2012-06-12 2020-03-30 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
JP6426606B2 (ja) 2012-08-03 2018-11-21 エスエービー，エルエルシー トランスジェニック動物におけるヒト抗体産生のための複合染色体工学
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
AU2014214863B2 (en) * 2013-02-06 2019-03-21 Duke University B cell lineage based immunogen design with humanized animals
LT2840892T (lt) 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
EP2958938B1 (en) 2013-02-20 2019-04-17 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
TW201542816A (zh) 2013-09-18 2015-11-16 Kymab Ltd 方法、細胞與生物體
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
AU2014360811B2 (en) 2013-12-11 2017-05-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
US10881085B2 (en) 2014-03-21 2021-01-05 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN113215196B (zh) * 2014-06-06 2024-09-03 瑞泽恩制药公司 用于修饰所靶向基因座的方法和组合物
BR112017000925B1 (pt) * 2014-07-14 2023-10-10 Washington State University Método de reprodução de porcos, método para gerar um porco sem nenhuma célula espermatogônica funcional, método de produção de um macho receptor e método de produção de porcos
EP3193592A1 (en) 2014-09-19 2017-07-26 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
GB201418713D0 (en) 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
EP3222718A4 (en) * 2014-11-20 2018-05-30 Kyoto University Method for knock-in of dna into target region of mammalian genome, and cell
LT3265123T (lt) 2015-03-03 2023-01-25 Kymab Limited Antikūnai, naudojimas ir būdai
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
FI3280257T3 (fi) 2015-04-06 2023-09-07 Regeneron Pharma Humanisoituja t-soluvälitteisiä immuunivasteita ei-ihmiseläimillä
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
EP3426271A4 (en) 2016-03-10 2019-10-16 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
WO2017163049A1 (en) 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
JP7198752B2 (ja) 2016-08-09 2023-01-04 カイマブ・リミテッド 抗ｉｃｏｓ抗体
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102319069B1 (ko) * 2016-11-04 2021-11-01 리제너론 파마슈티칼스 인코포레이티드 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
KR20190097094A (ko) 2016-12-21 2019-08-20 세파론, 인코포레이티드 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도
CN118140872A (zh) 2017-01-19 2024-06-07 欧莫诺艾比公司 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
KR20190129868A (ko) 2017-02-17 2019-11-20 데날리 테라퓨틱스 인크. 조작된 트란스페린 수용체 결합 폴리펩티드
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
CN110382526B (zh) 2017-02-17 2023-12-26 戴纳立制药公司 转铁蛋白受体转基因模型
GB2561352B (en) * 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
JP2020516590A (ja) 2017-04-14 2020-06-11 コールド ジェネシス， インコーポレイテッド 膀胱癌の治療方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
JP2020533960A (ja) 2017-08-01 2020-11-26 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 抗ｉｌ１ｒａｐ抗体
EP3697895A4 (en) * 2017-10-20 2021-12-08 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR PRODUCING GENETICALLY MODIFIED B-CELLS FOR EXPRESSION OF SELECTED ANTIBODIES
US20210345591A1 (en) 2017-12-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
CN116514959A (zh) 2018-03-24 2023-08-01 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途
TW202431987A (zh) 2018-03-26 2024-08-16 美商再生元醫藥公司 用於測試治療藥劑之人類化囓齒動物
CN108486125B (zh) * 2018-03-27 2024-01-05 重庆金迈博生物科技有限公司 一种核酸分子及其在制备人源单域抗体中的应用
CN108486126A (zh) * 2018-03-27 2018-09-04 重庆金迈博生物科技有限公司 一种核酸分子及其在人源化抗体中的应用
US20210251202A1 (en) 2018-06-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
GB2576914A (en) * 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
BR112021019128A2 (pt) 2019-04-09 2022-01-04 Abcuro Inc Anticorpos de depleção de membro 1 da subfamília g do receptor tipo lectina de célula assassina (klrg1)
IL293314A (en) 2019-11-29 2022-07-01 Kymab Ltd Treatment of physiological iron overload
KR20220110233A (ko) 2019-12-02 2022-08-05 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc ii 단백질 작제물 및 그의 용도
JP2023529846A (ja) 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
KR20230024822A (ko) * 2020-06-25 2023-02-21 주식회사 휴맵 이형접합성 형질전환 동물
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
KR20230084157A (ko) 2020-10-08 2023-06-12 주식회사 휴맵 인간화 면역글로불린 유전자좌를 포함하는 게놈을 가지는 형질전환 비인간-동물 제조방법
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
JP2024501286A (ja) 2020-12-23 2024-01-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
CA3227742A1 (en) 2021-07-26 2023-02-02 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023097236A1 (en) * 2021-11-24 2023-06-01 The Rockefeller University Compositions and methods for generating immunoglobulin knock-in mice
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US114985A (en) * 1871-05-16 Improvement in apparatus for cooling and preserving milk and other liquids
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4720449A (en) 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5859307A (en) 1992-02-04 1999-01-12 Massachusetts Institute Of Technology Mutant RAG-1 deficient animals having no mature B and T lymphocytes
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
JP4242447B2 (ja) 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
DE4331162A1 (de) 1993-09-14 1995-03-16 Bayer Ag Verfahren zur Herstellung von Cyaninfarbstoffen
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
WO1997049804A1 (en) 1996-06-26 1997-12-31 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US20020088019A1 (en) 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
ES2308327T3 (es) 1997-11-18 2008-12-01 Pioneer Hi-Bred International, Inc. Composiciones y metodos para modificacion genetica de plantas.
EP1034260B1 (en) 1997-12-05 2003-06-04 Europäisches Laboratorium Für Molekularbiologie (Embl) Novel dna cloning method relying on the e. coli rece/rect recombination system
EP0939120A1 (en) 1998-02-27 1999-09-01 Gesellschaft für biotechnologische Forschung mbH (GBF) Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU5867100A (en) 1999-05-03 2000-12-12 Medarex, Inc. Human antibodies to staphylococcus aureus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2307503A1 (en) * 2000-05-02 2001-11-02 Carlos F. Barbas Iii Peptides for use as a vaccine or treatment for hiv infection
CA2416701A1 (en) * 2000-07-21 2002-01-31 The United States Of America, As Represented By The Secretary Of Agricul Ture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) † 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002219841A1 (en) * 2000-11-16 2002-05-27 Cornell Research Foundation Inc. Vectors for conditional gene inactivation
CN1486365B (zh) 2000-11-17 2010-05-12 协和发酵麒麟株式会社 异种(人类)免疫球蛋白在克隆转基因有蹄类动物中的表达
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
AU2002246733B2 (en) * 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
EA012079B3 (ru) 2001-01-05 2018-07-31 Пфайзер Инк. Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения
AUPR446701A0 (en) * 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
JP2003000243A (ja) 2001-06-25 2003-01-07 Takachika Azuma 変異体の製造法
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
AU2002331077A1 (en) 2001-08-13 2003-03-03 Amberwave Systems Corporation Dram trench capacitor and method of making the same
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
US20050095712A1 (en) 2002-01-17 2005-05-05 Alberto Martin Mutations caused by activation-induced cytidine deaminase
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
EP1539946A4 (en) 2002-09-09 2006-03-15 California Inst Of Techn METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
CA2501981A1 (en) * 2002-10-01 2004-04-15 Mitos Pharmaceuticals, Inc. Nitroxide radioprotector formulations and methods of use
DE10251918A1 (de) 2002-11-08 2004-05-19 Horn, Carsten, Dipl.-Biochem. Dr. Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen
US7700356B2 (en) * 2002-11-08 2010-04-20 The United States Of America As Represented By The Secretary Of Agriculture System for gene targeting and producing stable genomic transgene insertions
CL2003002461A1 (es) 2002-11-27 2005-01-07 Dow Chemical Company Agroscien Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
GB2398784B (en) * 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
CN1326878C (zh) * 2003-04-29 2007-07-18 中国抗体制药有限公司 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
GB2403475B (en) † 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
AU2004257292A1 (en) * 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
US7663017B2 (en) * 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
US7604994B2 (en) 2003-09-03 2009-10-20 Morphotek, Inc. Genetically altered antibody-producing cell lines with improved antibody characteristics
US7205140B2 (en) 2003-10-20 2007-04-17 Campusgen Gmbh Nucleotide sequence for creatinine deiminase and method of use
KR20130133302A (ko) 2003-12-10 2013-12-06 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
JP2008507257A (ja) 2004-03-19 2008-03-13 アムゲン・インコーポレーテッド Ｖ遺伝子の操作を介したヒト抗ヒト抗体の危険性の低減
KR101443473B1 (ko) 2004-07-22 2014-09-22 에라스무스 유니버시티 메디컬 센터 로테르담 Ｖh 결합 영역의 분리 방법
FR2875239B1 (fr) 2004-09-10 2007-07-20 Inst Necker Ass Loi De 1901 Procede pour l'acceleration des mutations somatiques et son application en proteomique
WO2006029459A1 (en) 2004-09-13 2006-03-23 Evogenix, Inc Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
WO2006044492A2 (en) 2004-10-14 2006-04-27 Ingenious Targeting Laboratory, Inc. Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
DK2767161T3 (da) † 2004-10-19 2018-05-07 Regeneron Pharma Fremgangsmåde til generering af et dyr, der er homozygotisk for genetisk modifikation
EP1812578A2 (en) * 2004-10-22 2007-08-01 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in non-human transgenic animals
WO2006055704A2 (en) 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
PT1838733E (pt) 2004-12-21 2011-12-13 Medimmune Ltd Anticorpos direccionados a angiopoietina-2 e respectivos usos
AU2006242854A1 (en) 2005-04-29 2006-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
US20100154070A1 (en) * 2005-05-14 2010-06-17 Tian Xu PiggyBac as a Tool for Genetic Manipulation and Analysis in Vertebrates
EP1780272A1 (en) 2005-10-27 2007-05-02 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for enhancing somatic hypermutation, gene conversion and class switch recombination
GB0601513D0 (en) 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
US20090307787A1 (en) * 2006-01-25 2009-12-10 Franklin Gerardus Grosveld Generation of heavy-chain only antibodies in transgenic animals
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP2041177B1 (en) 2006-06-02 2011-12-14 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
ATE525093T1 (de) 2006-06-27 2011-10-15 Sanofi Pasteur Vaxdesign Corp Modelle für die bewertung von impfstoffen
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP2061812A4 (en) 2006-08-22 2010-06-09 G2 Inflammation Pty Ltd METHOD FOR THE PRODUCTION OF ANTIBODIES
US7778624B2 (en) * 2006-09-01 2010-08-17 Wanda Ying Li Outdoor umbrella with audio system
PT2769992T (pt) 2006-10-02 2021-03-11 Regeneron Pharma Anticorpos humanos com elevada afinidade para o receptor de il-4 humana
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
WO2008103474A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
DK2125889T3 (da) 2007-02-21 2014-04-14 Univ Massachusetts Humane antistoffer mod hepatitis c-virus (hcv) og anvendelser deraf
WO2008118970A2 (en) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
LT2602323T (lt) 2007-06-01 2018-04-10 Open Monoclonal Technology, Inc. Kompozicijos ir būdai endogeninių imunoglobulinų genams slopinti ir transgeniniams žmogaus idiotipo antikūnams gaminti
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
US7879984B2 (en) 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
KR101709495B1 (ko) 2007-08-10 2017-02-23 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
BRPI0818165B8 (pt) * 2007-10-12 2021-05-25 Hoffmann La Roche método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
US20110119779A1 (en) 2007-12-10 2011-05-19 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2252659A2 (en) 2008-01-25 2010-11-24 Cabot Corporation Method of preparing modified colored pigments
KR101409375B1 (ko) 2008-01-31 2014-06-18 삼성전자주식회사 반도체 메모리장치의 블록 디코딩 회로
WO2009118524A2 (en) 2008-03-26 2009-10-01 Iti Scotland Limited Efficient insertion of dna into embryonic stem cells
WO2009129247A2 (en) 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
PT2147594E (pt) 2008-06-27 2014-02-17 Merus B V Mamíferos não humanos que produzem anticorpos
NZ592308A (en) * 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN112690250B (zh) 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
CA2983133A1 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
US20110305692A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Antigen-binding contructs
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
WO2010113039A1 (en) 2009-04-03 2010-10-07 Medical Research Council Mutants of activation-induced cytidine deaminase (aid) and methods of use
WO2010151808A1 (en) 2009-06-26 2010-12-29 Sea Lane Biotechnologies, Llc Expression of surrogate light chains
GB0913102D0 (en) 2009-07-28 2009-09-02 Genome Res Ltd Animal models and therapeutic molesules
GB0911846D0 (en) 2009-07-08 2009-08-19 Genome Res Ltd Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP4215043A1 (en) 2009-07-08 2023-07-26 Kymab Limited Animal models and therapeutic molecules
US9273118B2 (en) 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011019844A1 (en) 2009-08-13 2011-02-17 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal cdrs
JP2013509878A (ja) 2009-11-05 2013-03-21 アナプティスバイオ インコーポレイティッド 鎖シャフリングおよび任意に体細胞超変異を用いる、改善された抗原結合物質の生成方法
AU2010320130B2 (en) 2009-11-17 2015-03-12 Sab, Llc Human artificial chromosome vector
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
DK2954779T3 (da) 2009-12-10 2019-05-13 Regeneron Pharma Mus, der frembringer tungkædeantistoffer
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
EP2571512B1 (en) 2010-05-17 2017-08-23 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
MX2012015298A (es) * 2010-06-22 2013-05-01 Regeneron Pharma Ratones con cadena ligera hibrida.
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
WO2012088313A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
HRP20191895T4 (hr) 2011-02-25 2023-05-12 Regeneron Pharmaceuticals, Inc. Adam6 miševi
LT3572517T (lt) 2011-08-05 2021-04-26 Regeneron Pharmaceuticals, Inc. Humanizuotos universalios lengvosios grandinės pelės
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
DK3311661T3 (da) 2011-09-19 2022-07-11 Kymab Ltd Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US20130102031A1 (en) 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20180295821A1 (en) 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CN104159444B (zh) 2011-12-20 2017-09-01 瑞泽恩制药公司 人源化的轻链小鼠
CN104202971B (zh) 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
JP2015509962A (ja) 2012-03-02 2015-04-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素に対するヒト抗体
WO2013134263A1 (en) 2012-03-06 2013-09-12 Regeneron Pharmaceuticals, Inc. Common light chain mouse
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
MY189533A (en) 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US8518765B1 (en) 2012-06-05 2013-08-27 Intermolecular, Inc. Aqua regia and hydrogen peroxide HCl combination to remove Ni and NiPt residues
SG10201913429WA (en) 2012-06-12 2020-03-30 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
US8962913B2 (en) * 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
CN104053778B (zh) 2012-11-09 2017-12-05 深圳市作物分子设计育种研究院 一种育性基因及其应用
IL293526A (en) 2012-12-12 2022-08-01 Harvard College Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
LT2840892T (lt) 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US20150033372A1 (en) 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US9783618B2 (en) * 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US20140331344A1 (en) 2013-05-03 2014-11-06 Kymab Ltd. Transgenic Animals
US20140331339A1 (en) 2013-05-03 2014-11-06 Kymab Limited Transgenic Non-Human Assay Vertebrates, Assays and Kits
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
JP7087648B2 (ja) * 2018-05-08 2022-06-21 トヨタ自動車株式会社 電池パック

Also Published As

Publication number Publication date
DK2604110T3 (da) 2017-02-13
US20170071174A1 (en) 2017-03-16
US11564380B2 (en) 2023-01-31
EP2517556A3 (en) 2013-07-17
JP2020150951A (ja) 2020-09-24
US20170105396A1 (en) 2017-04-20
ES2965212T3 (es) 2024-04-11
JP6876853B2 (ja) 2021-05-26
NZ597481A (en) 2013-10-25
CA2767436A1 (en) 2011-01-13
ES2974417T3 (es) 2024-06-27
CN105340834A (zh) 2016-02-24
US9505827B2 (en) 2016-11-29
EP3028564B1 (en) 2017-09-27
BR112012000536A2 (pt) 2020-08-11
SG2014010995A (en) 2014-05-29
US20140201856A1 (en) 2014-07-17
KR20130042461A (ko) 2013-04-26
US20140120582A1 (en) 2014-05-01
EP3622813A1 (en) 2020-03-18
JP5944312B2 (ja) 2016-07-05
EP3871497B1 (en) 2024-02-28
US20170099816A1 (en) 2017-04-13
EP2564695B1 (en) 2015-04-15
EP3028564A1 (en) 2016-06-08
AU2010269978B2 (en) 2016-11-03
EP3622815B1 (en) 2023-04-05
ES2557737T3 (es) 2016-01-28
JP2012532598A (ja) 2012-12-20
US9434782B2 (en) 2016-09-06
PL2564695T3 (pl) 2015-10-30
HUE055817T2 (hu) 2021-12-28
EP3871497C0 (en) 2024-02-28
HK1180535A1 (en) 2013-10-25
DK2517556T4 (da) 2023-05-15
HK1162119A1 (en) 2012-08-24
DK2517557T3 (da) 2016-05-30
CN102638971B (zh) 2015-10-07
SMT201300046B (it) 2013-07-09
EP2798950B2 (en) 2023-03-22
NO2792236T3 (da) 2018-04-14
US20200352145A1 (en) 2020-11-12
US20200352144A1 (en) 2020-11-12
EP3241435B1 (en) 2021-05-26
US20230225302A1 (en) 2023-07-20
DK2517556T3 (da) 2016-01-11
CN105340834B (zh) 2018-11-06
EP2604110A3 (en) 2013-08-14
DK2792236T4 (da) 2023-05-15
US10064398B2 (en) 2018-09-04
EP4014729C0 (en) 2024-08-07
HRP20130253T1 (hr) 2013-05-31
EP2792236B2 (en) 2023-03-22
EP3241435A1 (en) 2017-11-08
EP3622814A1 (en) 2020-03-18
CN102638971A (zh) 2012-08-15
JP2020028296A (ja) 2020-02-27
EP2517557B2 (en) 2023-08-02
US20150334998A1 (en) 2015-11-26
DK2421357T3 (da) 2013-04-15
ES2884309T3 (es) 2021-12-10
US9447177B2 (en) 2016-09-20
US20140201854A1 (en) 2014-07-17
US11606941B2 (en) 2023-03-21
DK3028565T3 (da) 2017-11-13
US20230263143A1 (en) 2023-08-24
DK2798950T4 (da) 2023-05-15
HK1201026A1 (en) 2015-08-21
CY1126083T1 (el) 2023-11-15
EP2604111A3 (en) 2013-12-18
EP2421357A1 (en) 2012-02-29
EP3871498B1 (en) 2024-09-25
EP2517557A3 (en) 2013-07-24
US20120204278A1 (en) 2012-08-09
US20130042331A2 (en) 2013-02-14
US20170051045A1 (en) 2017-02-23
EP2421357B1 (en) 2013-01-23
JP2020156502A (ja) 2020-10-01
JP2017086084A (ja) 2017-05-25
EP3622814C0 (en) 2023-11-08
US20160345552A1 (en) 2016-12-01
AU2021200079B2 (en) 2023-11-09
JP6612275B2 (ja) 2019-11-27
EP2798950B1 (en) 2017-04-19
JP6930695B2 (ja) 2021-09-01
EP3622815A1 (en) 2020-03-18
EP3888457B1 (en) 2024-05-15
US20170099817A1 (en) 2017-04-13
EP2792236A2 (en) 2014-10-22
EP2517556B1 (en) 2015-11-18
EP2604110B1 (en) 2016-11-30
US20200337280A1 (en) 2020-10-29
AU2021200079A1 (en) 2021-03-18
EP2517556B2 (en) 2023-03-22
AU2018206729C1 (en) 2023-08-10
US20160150768A1 (en) 2016-06-02
ES2537239T3 (es) 2015-06-03
EP2604110A2 (en) 2013-06-19
US20130318643A1 (en) 2013-11-28
DK3028564T3 (da) 2017-11-13
DK2517557T4 (da) 2023-09-25
EP4215043A1 (en) 2023-07-26
PT2517556E (pt) 2016-01-20
EP3028565B1 (en) 2017-09-27
EP3028564B2 (en) 2024-01-24
ES2978496T3 (es) 2024-09-13
EP3888457A1 (en) 2021-10-06
US20160044900A1 (en) 2016-02-18
DK3028564T4 (da) 2024-04-22
SI2421357T1 (sl) 2013-06-28
EP2564695A1 (en) 2013-03-06
US20160345551A1 (en) 2016-12-01
AU2016244326B2 (en) 2018-04-26
SG177380A1 (en) 2012-02-28
KR101875233B1 (ko) 2018-07-05
US20240057572A1 (en) 2024-02-22
JP2020156503A (ja) 2020-10-01
DK3622813T3 (da) 2021-05-03
US20170101482A1 (en) 2017-04-13
US20140150125A1 (en) 2014-05-29
US20170094956A1 (en) 2017-04-06
US20230270088A1 (en) 2023-08-31
DK3241435T3 (da) 2021-08-23
PT2564695E (pt) 2015-06-03
US20150040250A1 (en) 2015-02-05
SI3241435T1 (sl) 2021-11-30
DK2798950T3 (da) 2017-05-22
US20150113669A1 (en) 2015-04-23
AU2010269978A1 (en) 2012-02-02
JP2015126736A (ja) 2015-07-09
PT3241435T (pt) 2021-08-26
EP3622813B1 (en) 2021-02-17
EP3871497A1 (en) 2021-09-01
DK2564695T3 (da) 2015-05-26
WO2011004192A1 (en) 2011-01-13
US11812731B2 (en) 2023-11-14
EP2798950A1 (en) 2014-11-05
US20200375158A1 (en) 2020-12-03
ES2948572T3 (es) 2023-09-14
PT2421357E (pt) 2013-04-18
HK1172207A1 (zh) 2013-04-19
EP2792236A3 (en) 2014-11-12
EP2604111A2 (en) 2013-06-19
US20140150126A1 (en) 2014-05-29
US20170099815A1 (en) 2017-04-13
PL3241435T3 (pl) 2021-12-13
US20140134156A1 (en) 2014-05-15
HK1202373A1 (en) 2015-10-02
EP2517557A2 (en) 2012-10-31
JP6088562B2 (ja) 2017-03-01
EP3888457C0 (en) 2024-05-15
LT3241435T (lt) 2021-10-25
DK3622813T4 (da) 2024-09-16
US20120167237A1 (en) 2012-06-28
US20140182003A1 (en) 2014-06-26
HRP20211253T1 (hr) 2021-11-12
EP4014729B1 (en) 2024-08-07
PL2421357T3 (pl) 2013-07-31
PL2517556T3 (pl) 2016-03-31
HUE061788T2 (hu) 2023-08-28
DK3622815T3 (da) 2023-06-26
EP3622813B2 (en) 2024-06-19
AU2016244326A1 (en) 2016-11-03
AU2018206729A1 (en) 2018-08-02
EP2792236B1 (en) 2017-11-15
EP3028565A1 (en) 2016-06-08
US10165763B2 (en) 2019-01-01
DK2792236T3 (da) 2018-01-02
JP6876854B2 (ja) 2021-05-26
EP2517557B1 (en) 2016-04-13
EP2517556A2 (en) 2012-10-31
EP3622814B1 (en) 2023-11-08
ES2403087T3 (es) 2013-05-14
EP3871498A1 (en) 2021-09-01
AU2018206729B2 (en) 2020-10-08
EP4014729A1 (en) 2022-06-22
JP7141427B2 (ja) 2022-09-22

Similar Documents

Publication Publication Date Title
DK3241435T3 (da) Dyremodeller og terapeutiske molekyler
DK2437762T3 (da) Kunstige tårer og terapeutiske anvendelser
HK1200872A1 (en) Animal models and therapeutic molecules
FI20085334A (fi) Harjoitusmenetelmä ja -järjestelmä
DK2437830T4 (da) Anordning til lægemiddelleveringsindretning og lægemiddelleveringsindretning
BRPI0917684A2 (pt) método terapêutico homeopático
DK2274619T3 (da) Slimhindereceptor og anvendelser deraf
DK2252688T3 (da) Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf
DK2341900T3 (da) Lægemiddelprodukt og behandling
DK2293846T3 (da) Depsipeptider og deres terapeutiske anvendelse
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
GB0911846D0 (en) Animal models and therapeutic molecules
GB0913102D0 (en) Animal models and therapeutic molesules
ES1071307Y (es) Carreton para entrenamiento en practicas de acoso-derribo y rejoneo
FI20080332A0 (fi) Terapeuttisia molekyylejä
EE00836U1 (et) Teraapiline lelu
DK2349383T3 (da) Hjertehjælpeindretning og system
DK2244773T3 (da) Systemer og fremgangsmåder til ex vivo-lungepleje
IT1396965B1 (it) Dispositivo terapeutico